Aortic & peripheral vascular disease
Validation of the Academic Research Consortium High Bleeding Risk (Academic Research Consortium for High Bleeding Risk (ARC-HBR)) criteria in patients undergoing peripheral endovascular interventions
Authors' conclusion
80.3% of PAD patients undergoing EVT for femoropopliteal artery lesions with contemporary drug-coated devices met the ARC-HBR criteria.
Study context
- Population
- Peripheral artery disease (PAD) patients undergoing endovascular therapy (EVT) with drug-coated devices for femoropopliteal artery lesions, May 2012–December 2019
- Participants
- 542 patients
- Exposure
- HBR vs non-HBR by ARC-HBR criteria
- HBRn = 435
- Outcome
- Major bleeding events (BARC type 3 or 5)
- Follow-up
- 5 years
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Cumulative major bleeding
P < 0.001
Observational data: associations, not effects.
Further findings
Major bleeding by number of ARC-HBR criteria · 5 years
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Mortality after major bleedingMajor bleedingvs No major bleeding | 5.42 (2.91–10.1) | P < 0.001 | |
| 0.050.21520Adjusted hazard ratio (log scale) |
- Major bleeding by number of ARC-HBR criteria: p<0.001
Predictors of major bleeding
- Severe CKD, HF and severe anaemia predicted major bleeding
Original publication
Validation of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in patients undergoing peripheral endovascular interventions. EuroIntervention. Published 3 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →